Key Decisions in HIV Care: Polypharmacy and Cardiovascular Risk Considerations in Older PWH

In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for ART use in older PWH, including:

• DHHS, EACS, IAS, and WHO recommendations for first-line ART
• Virologic outcomes for older PWH in clinical trials and results from the HealthHIV Second Annual National Survey
• Polypharmacy and its potential consequences, including common non-ARV medications prescribed in the VACS cohort, drug–drug interactions with common concomitant medications, common comorbidities in older PWH, and drug–disease state interactions including renal and hepatic impairment
• Cardiovascular risk considerations including data from the D:A:D study and RESPOND cohort and lipid changes in the TANGO study of switching to DTG/3TC from TAF-based ART

Presenters:

Jonathan Appelbaum, MD, FACP, AAHIVS
Laurie L. Dozier Jr, MD, Education Director
Professor of Internal Medicine  
Chair, Department of Clinical Sciences
Florida State University College of Medicine
Tallahassee, Florida  

Jens D. Lundgren, MD, DMSc
Professor
Rigshospital, University of Copenhagen
Copenhagen, Denmark
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark  

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at:
https://bit.ly/3miT6qH

See the entire program at: 
https://bit.ly/2TXTYWx

 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.